Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.

Mohamed Abdel HamidNizar S AbdelfattahJamshid SalamzadehSahar T A AbdelazizAhmed M SabryKhaled M MouradAzza A ShehabBaruch D Kuppermann

Published in: International journal of retina and vitreous (2021)

Switching to intravitreal aflibercept therapy in a cohort of neovascular AMD patients resistant to chronic bevacizumab and/or ranibizumab injections can lead to significant visual improvement in the short term and sustained reduction of central macular thickness over 1 year of followup.

Keyphrases

age related macular degeneration
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
metastatic colorectal cancer
patient reported outcomes
diabetic retinopathy
endothelial cells
cell therapy
drug induced